Healthcare
Clinuvel Pharmaceuticals Ltd. Sponsored ADR(CLVLY)
Live Price
Offline$6.94
+10.86% today
1Y Change
+5.19%
Window
Jun 25, 2025 โ Jun 24, 2026
- Market Cap
- $480.00M
- Revenue Growth
- +7.8%
- EPS Growth
- 0.0%
- Dividend Yield
- 0.5%
Coverage: 250 bars ยท Jun 25, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Clinuvel Pharmaceuticals Ltd. Sponsored ADR (CLVLY) is a Healthcare stock with a market cap of $480.00M and listed on OTC. The stock last traded around $6.94 and up 5.2% across the available one-year price window (Jun 25, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of +7.8%, EPS growth of 0.0%, a dividend yield of 0.5%. What stands out right now is revenue +7.8%, EPS 0.0%, free cash flow +29.6% with operating margin 39.4% and ROIC 11.1%. The dividend is present but secondary, with a yield around 0.5%. Valuation is more restrained than many high-expectation growth names at P/E 14.7 and price/sales 5.0. Stock Foundry combines CLVLY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+7.8% vs +7.6% peer median
Operating Margin
Above sector median
+39.4% vs +19.4% peer median
P/E
Below sector median
14.7 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on Feb 25, 2026 with an EPS surprise of -25.9% and a revenue surprise of +2.2%.
The setup is mixed rather than one-directional
Revenue is +7.8% and EPS is 0.0%, while operating margin sits near 39.4%.
The next real check-in already has a date
The next earnings event is scheduled for Sep 1, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -2.1% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Feb 25, 2026 | -25.9% | -4.4% | -14.4% | -17.0% |
2025 Aug 21, 2025 | +57.4% | +5.9% | +7.2% | -0.1% |
2025 Feb 26, 2025 | +27.1% | +3.4% | +0.9% | +13.2% |
Benchmark Edge
CLVLY vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CLVLY
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CLVLY Max Drawdown
-29.34%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CLVLY and SPY.
Company Overview
Clinuvel Pharmaceuticals Ltd. Sponsored ADR
OTC
Clinuvel Pharmaceuticals Ltd. Sponsored ADR represents the American Depositary Receipts (ADRs) for Clinuvel Pharmaceuticals, a global biopharmaceutical company headquartered in Melbourne, Australia. The primary function of this ADR is to enable United States investors to invest in Clinuvel Pharmaceuticals without dealing with foreign exchange complexities or cross-border regulations. Clinuvel Pharmaceuticals focuses on developing and commercializing treatments for severe skin disorders and is renowned for its work in dermatology. The company has gained recognition for developing innovative therapies that protect skin from harmful exposure to ultra-violet radiation, such as EPP (erythropoietic protoporphyria) and Vitiligo treatments, which address niche but impactful medical conditions. These ADRs play a significant role in broadening the firm's investor base by providing easier access for U.S. institutional and retail investors. Consequently, Clinuvel's advancements in photoprotection and innovative pigmentary disorder solutions are gaining increased attention, both in the biotechnology industry and financial markets globally. By holding Sponsored ADRs, investors can participate in the company's growth story while benefiting from the efficiencies of the U.S financial market. This structure underscores Clinuvel's commitment to expanding its presence and contributing to dermatological therapeutic innovation.
- Leadership
- Dr. Philippe Jacques Wolgen M.B.A., M.D.
- Street Address
- 535 Bourke Street, Level 22
- Mailing
- Melbourne, VIC, 3000
- Region
- Melbourne, VIC, Australia
- Last Updated
- May 8, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 14.7
- EV/EBITDA
- 10.7
- Price/Sales
- 5.0
- Price/Book
- 1.9
Growth
- Revenue
- +7.8%
- EPS
- 0.0%
- Free Cash Flow
- +29.6%
Profitability
- Gross Margin
- 63.7%
- Operating Margin
- 39.4%
- Net Margin
- 33.8%
- ROE
- 13.3%
- ROIC
- 11.1%
Balance Sheet
- Debt/Equity
- 0.00
- Current Ratio
- 14.64
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.